These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 15975043

  • 1. Metabolism of designer drugs of abuse.
    Staack RF, Maurer HH.
    Curr Drug Metab; 2005 Jun; 6(3):259-74. PubMed ID: 15975043
    [Abstract] [Full Text] [Related]

  • 2. Piperazine compounds as drugs of abuse.
    Arbo MD, Bastos ML, Carmo HF.
    Drug Alcohol Depend; 2012 May 01; 122(3):174-85. PubMed ID: 22071119
    [Abstract] [Full Text] [Related]

  • 3. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis.
    Maurer HH, Kraemer T, Springer D, Staack RF.
    Ther Drug Monit; 2004 Apr 01; 26(2):127-31. PubMed ID: 15228152
    [Abstract] [Full Text] [Related]

  • 4. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry.
    Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH.
    J Mass Spectrom; 2003 Jun 01; 38(6):659-76. PubMed ID: 12827635
    [Abstract] [Full Text] [Related]

  • 5. Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry.
    Springer D, Fritschi G, Maurer HH.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Nov 05; 796(2):253-66. PubMed ID: 14581066
    [Abstract] [Full Text] [Related]

  • 6. Piperazine designer drugs induce toxicity in cardiomyoblast h9c2 cells through mitochondrial impairment.
    Arbo MD, Silva R, Barbosa DJ, da Silva DD, Rossato LG, Bastos Mde L, Carmo H.
    Toxicol Lett; 2014 Aug 17; 229(1):178-89. PubMed ID: 24968061
    [Abstract] [Full Text] [Related]

  • 7. Hepatotoxicity of piperazine designer drugs: Comparison of different in vitro models.
    Dias-da-Silva D, Arbo MD, Valente MJ, Bastos ML, Carmo H.
    Toxicol In Vitro; 2015 Aug 17; 29(5):987-96. PubMed ID: 25863214
    [Abstract] [Full Text] [Related]

  • 8. Piperazine designer drugs elicit toxicity in the alternative in vivo model Caenorhabditis elegans.
    Souto C, Göethel G, Peruzzi CP, Cestonaro LV, Garcia I, Ávila DS, Eifler-Lima V, Carmo H, Bastos ML, Garcia SC, Arbo MD.
    J Appl Toxicol; 2020 Mar 17; 40(3):363-372. PubMed ID: 31755144
    [Abstract] [Full Text] [Related]

  • 9. Metabolism of designer drugs of abuse: an updated review.
    Meyer MR, Maurer HH.
    Curr Drug Metab; 2010 Jun 01; 11(5):468-82. PubMed ID: 20540700
    [Abstract] [Full Text] [Related]

  • 10. Detection of 1-benzylpiperazine, 1-(3-trifluoromethylphenyl)-piperazine, and 1-(3-chlorophenyl)-piperazine in 3,4-methylenedioxymethamphetamine-positive urine samples.
    Dickson AJ, Vorce SP, Holler JM, Lyons TP.
    J Anal Toxicol; 2010 Oct 01; 34(8):464-9. PubMed ID: 21819791
    [Abstract] [Full Text] [Related]

  • 11. Chemistry, pharmacology, and metabolism of emerging drugs of abuse.
    Maurer HH.
    Ther Drug Monit; 2010 Oct 01; 32(5):544-9. PubMed ID: 20683389
    [Abstract] [Full Text] [Related]

  • 12. Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry.
    Staack RF, Maurer HH.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Dec 25; 798(2):333-42. PubMed ID: 14643514
    [Abstract] [Full Text] [Related]

  • 13. The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine.
    Schep LJ, Slaughter RJ, Vale JA, Beasley DM, Gee P.
    Clin Toxicol (Phila); 2011 Mar 25; 49(3):131-41. PubMed ID: 21495881
    [Abstract] [Full Text] [Related]

  • 14. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives.
    Kraemer T, Maurer HH.
    Ther Drug Monit; 2002 Apr 25; 24(2):277-89. PubMed ID: 11897973
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes.
    Springer D, Paul LD, Staack RF, Kraemer T, Maurer HH.
    Drug Metab Dispos; 2003 Aug 25; 31(8):979-82. PubMed ID: 12867484
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step.
    Staack RF, Theobald DS, Paul LD, Springer D, Kraemer T, Maurer HH.
    Xenobiotica; 2004 Feb 25; 34(2):179-92. PubMed ID: 14985146
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.